PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
96.69%
Cash & equivalents yoy growth at least 1.5x TRVN's 17.60%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
96.69%
Below half of TRVN's -10.15%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
119.86%
Other current assets growth < half of TRVN's -17.71%. David Dodd sees a leaner approach to short-term items.
94.31%
Below half of TRVN's -10.34%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-6.34%
≥ 1.5x TRVN's -3.68%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.92%
≥ 1.5x TRVN's -3.20%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Below half of TRVN's -9.33%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-11.61%
Less than half of TRVN's 12.57%. David Dodd sees a more disciplined AP approach or lower volume.
-42.55%
Above 1.5x TRVN's -20.51%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
11.61%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-11.56%
Similar yoy to TRVN's -14.81%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.36%
Above 1.5x TRVN's -1.94%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-11.23%
Similar yoy to TRVN's -10.63%. Walter Schloss sees parallel expansions in total liabilities.
36.01%
Higher Common Stock (Book Value) Growth compared to TRVN's zero value, indicating worse performance.
-2.61%
≥ 1.5x TRVN's -1.19%. David Dodd sees higher yoy retained profits than competitor.
-6.95%
Less than half of TRVN's 233.33%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
193.87%
Below half TRVN's -8.61%. Michael Burry sees potential underperformance in building shareholder capital.
78.33%
Below half TRVN's -9.33%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-9.95%
50-75% of TRVN's -13.84%. Bruce Berkowitz sees relatively smaller yoy debt additions.
-116.79%
50-75% of TRVN's -232.51%. Bruce Berkowitz notes comparatively lower net debt expansion.